Exenatide - Newron Sweden

Drug Profile

Exenatide - Newron Sweden

Alternative Names: Exendin-4 - NeuroNova AB

Latest Information Update: 13 Sep 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroNova AB
  • Developer Newron Sweden AB
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 13 Sep 2013 Discontinued - Preclinical for Parkinson's disease in Sweden (Parenteral)
  • 21 Oct 2009 Pharmacodynamics data from animal studies in Parkinson's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 31 Oct 2006 NeuroNova AB is seeking partnership opportunities to develop exenatide for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top